GlassScriptPhysician profile
Deonna Campbell
NPI 1821664350
$2,276.36
in general payments reported to CMS, 2019-2025
26 companies · $568 in 2025
The $568 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.56 · 2022: $319 · 2023: $659 · 2024: $701 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,928.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $654.17 | 2022-2025 | |
| Corcept Therapeutics | $254.34 | 2023-2025 | Korlym |
| Indivior INC. | $185.58 | 2022-2025 | Sublocade |
| Axsome Therapeutics, INC. | $134.80 | 2023-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $119.42 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.44 | 2025 | Caplyta |
| Novo Nordisk INC | $104.45 | 2021-2025 | Rybelsus, Ozempic |
| Amgen INC. | $78.39 | 2023-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $75.76 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.44 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $67.12 | 2022-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $56.11 | 2025 | Hetlioz, Fanapt |
| Lilly USA, LLC | $49.19 | 2022-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $39.27 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Ironshore Pharmaceuticals INC. | $38.83 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $37.03 | 2023-2024 | Rexulti, Vyepti |
| Paratek Pharmaceuticals, INC. | $32.50 | 2023-2024 | Nuzyra |
| Mylan Specialty L.P. | $30.43 | 2021-2022 | |
| Alkermes, INC. | $23.14 | 2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $22.69 | 2023 | Invega Sustenna |
| Ardelyx, INC. | $21.67 | 2025 | Ibsrela |
| Braeburn INC. | $18.09 | 2025 | Brixadi |
| Gilead Sciences, INC. | $16.18 | 2025 | |
| Boston Scientific Corporation | $15.28 | 2024 | Bodyguardian |
| Supernus Pharmaceuticals, INC. | $14.33 | 2023 | Qelbree |
| Exact Sciences Corporation | $12.71 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deonna Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.